Steffen Pfeuffer

No current affiliations available for this person. The person is no longer active at the university.

Publications

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation Pfeuffer S, Schmidt R, Ruck T, Kleinschnitz C, Lee DH, Linker R, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wiendl H, Meuth SG (2019) In: Journal of Neurology, 266(1), 165-173. doi:10.1007/s00415-018-9117-z Research article (journal) \| Peer reviewed \| Published
Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study Riepl E, Pfeuffer S, Ruck T, Lohmann H, Wiendl H, Meuth SG, Johnen A (2018) In: Frontiers in Neurology, 8. doi:10.3389/fneur.2017.00730 Research article (journal) \| Peer reviewed \| Published
T-cell mediated secondary autoimmunity following alemtuzumab treatment: 2 cases of vitiligo Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Wiendl H, Meuth SG, Klotz L (2018) In: Multiple Sclerosis, 24(2), 711-712. Research article (journal) \| Peer reviewed \| Published
Alemtuzumab-induced changes in cerebrospinal fluid immune cell pattern - a prospective observational study Pfeuffer S, Ruck T, Lammerding L, Schulte-Mecklenbeck A, Gross CC, Wiendl H, Klotz L, Meuth SG (2018) In: Multiple Sclerosis, 24(2), 677-678. Research article (journal) \| Peer reviewed \| Published
Comparison of high-dose intravenous corticosteroids and therapeutic plasma exchange in acute relapsing multiple sclerosis Lammerding L, Pfeuffer S, Bormann E, Sauerland C, Ruck T, Brand M, Schilling M, Kleinschnitz C, Wiendl H, Meuth SG (2018) In: Multiple Sclerosis, 24(2), 262-263. Research article (journal) \| Peer reviewed \| Published

Show all publications